Introduction
Rapid influenza diagnostic tests (RIDTs) detect Influenza A and B viral nucleoprotein (NP) from respiratory specimens. Specific antibodies are used to capture the NP on a membrane with test results generated in 10-15 minutes. Rapid influenza diagnostic tests have been shown to be highly specific; however, several reports have shown that RIDT analytical and clinical sensitivity varies. [1] [2] [3] Additionally, the type of specimen collected, time from illness onset to collection of respiratory specimen, and prevalence of influenza activity in the population have been shown to affect RIDT results. 4 The emergence of a variant virus in 2009 highlighted the need to evaluate the reactivity of RIDTs as the NP from influenza A(H1N1)pdm09 originated from swine rather than human viruses. 5 Reduced reactivity of RIDTs with influenza A(H1N1)pdm09 in comparison with seasonal influenza viruses [6] [7] [8] [9] [10] is of public health concern. Rapid influenza diagnostic tests were found to be capable of detecting influenza A(H1N1)pdm09 in respiratory specimens, but many infections could be missed, especially in specimens with low viral loads. 10 Between 1990 and 2010, 27 human cases of infection with variant influenza viruses that contain one or more gene segments derived from viruses of swine origin were identified in the United States. 11 These variant viruses were of different subtype [A(H1N1)v, A(H1N2)v, and A(H3N2)v] and genome constellations. In 2010, the increase in the number of human infections with H3N2v viruses prompted the preparation of a candidate vaccine virus, A ⁄ Minnesota ⁄ 11 ⁄ 2010 (H3N2)v. In July 2011, the first human case of infection with a new reassortant influenza A(H3N2)v virus containing the matrix (M) gene from influenza A(H1N1)pdm09 virus was detected. 12, 13 From July 2011 through August 9, 2012, a total of 166 human infections with H3N2v viruses have been reported. 13, 14 Increasing numbers of human infections with variant viruses prompted the investigation of the analytical reactivity of FDA-cleared RIDTs with these viruses. To determine whether RIDTs can detect influenza A(H3N2)v in addition to A(H1N1)v and A(H1N2)v viruses, seven FDA-cleared RIDTs were evaluated analytically with variant viruses as well as with circulating human influenza A(H3N2) and A(H1N1)09pdm viruses. A public health message describing updated influenza A(H3N2)v virus case counts and an abbreviated data set was published recently in the Morbidity and Mortality Weekly Report.
14 This manuscript provides additional data and discussion describing reactivity and genetic comparisons with seasonal viruses and additional influenza A variant viruses.
Materials and methods

RIDTs
Seven FDA-cleared RIDTs were evaluated ( 
Viruses
Influenza A viruses used in the study are listed in Table 2 . The viruses were grown in Madin-Darby Canine Kidney cells from ATCC collection (CCL-34) as previously described.
15
The 50% tissue culture infectious dose (TCID 50 ⁄ ml) was measured to estimate the amount of infectious virus in a sample as described. 16 
Phylogenetic analysis
The evolutionary history of the influenza A NP gene was inferred by using the maximum likelihood method based on the data-specific model. 17 The tree with the highest log likelihood ()21797AE5176) is shown. Initial tree(s) for the heuristic search were obtained automatically as follows. When the number of common sites was <100 or less than one-fourth of the total number of sites, the maximum parsimony method was used; otherwise, BIONJ method with MCL distance matrix was used. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis involved 89 nucleotide sequences, and GISAID accession numbers are listed in Table S1 . Codon positions included were 1st + 2nd + 3rd + Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 1357 positions in the final data set. Evolutionary analyses were conducted in MEGA5.
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Results Table 2 shows the lowest virus concentration (TCID 50 ⁄ ml) detected by each RIDT for each influenza virus. All RIDTs detected the seasonal influenza A ⁄ Georgia ⁄ 01 ⁄ 2011 (H3N2) virus, although at different infectious virus titers varying from 10 1AE0 TCID 50 ⁄ ml (DirectigenÔ, QuickVue Ò were unable to detect two of three influenza A(H1)v viruses in this evaluation.
As the NP of influenza viruses is the target for all evaluated RIDTs, we compared predicted amino acid sequences of the NP based on available genetic data for tested viruses (Table 3) Figure 1 further demonstrates that although the NP genes in North American swine and human seasonal influenza viruses are derived from a common ancestor related to the A(H1N1) from 1918, separate species-specific evolutionary paths have since occurred. North American swine NP is quite divergent from the NP of seasonal human influenza A viruses but more closely genetically related to NP from influenza A(H1N1)pdm09 viruses. RIDT, rapid influenza diagnostic test. TCID 50 ⁄ ml, infectious titer of stock virus; U, undetected at any concentration tested.
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Discussion
As demonstrated by this evaluation, RIDTs may or may not detect the presence of NP derived from influenza viruses that are circulating in swine. Genetic sequence analysis indicates divergence of the NP of influenza A variant viruses and the A(H1N1)pdm09 virus compared with the NP of seasonal influenza A viruses, which may account for reduced reactivity with some RIDTs. It is important to note that all RIDTs have different proprietary antibodies to capture and detect NP, making it impossible to predict which RIDTs may detect NP that evolved from viruses that are not of human origin. As indicated in the manufacturer package inserts, influenza A viruses that have undergone minor amino acid changes in the target epitope region or regions may cause the antibodies to be less sensitive or not sensitive at all. Although the NP gene sequences are almost identical among variant viruses, several variant viruses were tested in this study because influenza virus preparations can be different in terms of amount of infectious ⁄ noninfectious virus, protein concentration, etc. This may account for differences in reactivity of different viruses with RIDTs despite having similar infectious virus titers. This first study to assess analytical reactivity of FDAcleared RIDTs with influenza A variant viruses has some limitations. Only seven RIDTs were evaluated when currently there are 15 FDA-cleared RIDTs of which six are CLIA-waived for use in point-of-care settings. 4 Cell culture virus isolates were used for this study. Limited volumes prevented a comparison of all seven RIDTs with clinical specimens. As in most analytical evaluations, influenza viruses in this study were characterized by their infectious 
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virus titer but not by the NP concentration. Infectious virus titer can vary among preparations of the same virus, and the titers were not normalized for the purposes of this evaluation. A side-by-side performance evaluation of all cleared assays with multiple influenza virus preparations, dilutions, and replicates would provide a direct analytical comparison of all FDA-cleared RIDTs. This study was conducted to provide public health guidance for the use of RIDTs when a novel influenza virus infection is suspected. It is important for clinicians to minimize the occurrence of false RIDT results by strictly following the manufacturer's instructions, collecting specimens soon after onset of influenza-like illness symptoms (ideally within the first 72 hours), and confirming RIDT results by sending a specimen to a public health laboratory. 4 Qualified U.S. public health laboratories and global National Influenza Centers may utilize the CDC Flu rRT-PCR Panel and a real-time RT-PCR assay, which allows for the preliminary identification of influenza variant viruses possessing the swine NP gene. 13 This evaluation reinforces the fact that a negative RIDT result should not be considered as conclusive evidence of a lack of infection with influenza virus and emphasizes that this may particularly be the case for influenza A(H3N2)v viruses.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Table S1 . GISAD accession numbers for sequences in phylogenetic tree.
